Estonia
Tuberculosis profile
| High HIV burden | High MDR-TB burden |
Population  2013 1.3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.032 (0.031–0.032) 2.5 (2.4–2.5)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.39 (0.28–0.52)
Prevalence  (includes HIV+TB) 0.34 (0.15–0.61) 27 (12–47)
Incidence  (includes HIV+TB) 0.29 (0.27–0.32) 22 (21–25)
Incidence (HIV+TB only) 0.034 (0.03–0.04) 2.6 (2.3–3.1)
Case detection, all forms (%) 92 (82–97)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 17 (12–24) 48 (32–63)
MDR-TB cases among notified pulmonary
TB cases
37 (25–51) 27 (18–35)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 174   26
Pulmonary, clinically diagnosed 40   7
Extrapulmonary 11   5
       
Total new and relapse 263    
Previously treated, excluding relapses 23    
Total cases notified 286    
Among 263 new and relapse cases:
1 (<1%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 180 (103%) 44 (72%) 222
Laboratory-confirmed RR-/MDR-TB cases     54
Patients started on MDR-TB treatment     40
TB/HIV 2013 Number (%)
TB patients with known HIV status 277 (97)
HIV-positive TB patients 36 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 24 (67)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 74
Previously treated cases, excluding relapse, registered in 2012 20
HIV-positive TB cases, all types, registered in 2012 47
RR-/MDR-TB cases started on second-line treatment in 2011 61
XDR-TB cases started on second-line treatment in 2011 29
Laboratories 2013  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 7.8
Drug susceptibility testing (per 5 million population) 7.8
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 97%
% Funded internationally 3%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-26 Data: www.who.int/tb/data